Integrated R&D Services

Drug R&D Services
- By Target
  - COX-2
  - H2 Receptor
  - Proton Pump
  - ClC-2
  - Guanylate Cyclase-C
  - NHEs
  - JAKs
  - Phosphodiesterases
- By Research Phase
IVD R&D Services
Vaccine R&D Services
Preclinical Gastroenterology & Hepatology CRO Services
- Preclinical Gastroenterology CRO Services
- Preclinical Hepatology CRO Services

Get Free Quote

* Name

Phone

* Email

* Products/Services Interested

Project Description

* Please note that all of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.

Pharmacokinetic Services for GI & Hepatic Disease Drug

Inquiry

With our expertise and cutting-edge research capabilities, Ace Therapeutics is dedicated to providing comprehensive pharmacokinetic (PK) evaluations to support drug development. Our company utilizes specialized in vitro and in vivo models to study how drugs are absorbed, distributed, metabolized, and excreted within the gastrointestinal (GI) tract and liver. Some key services we offer include mass-balance and toxicokinetic studies, drug metabolism and interaction profiling, as well as bioanalytical method development and validation.

Our Pharmacokinetic Services for GI & Hepatic Disease Drugs

Absorption Studies Distribution Studies Metabolism Studies Bile Excretion Studies Transporter Interaction Studies Plasma Protein Binding Studies

Characterize absorption mechanisms using Caco-2 cell monolayers, intestinal organoids, and chamber assays to measure permeability.
Conduct ex vivo tissue imaging and in situ intestinal loop experiments in rodents to elucidate regional and temporal uptake profiles.

Utilize imaging modalities such as positron emission tomography (PET) or magnetic resonance imaging (MRI) to track the distribution of radiolabeled or contrast-enhanced drugs in real-time or non-invasively.
Conduct ex vivo experiments using tissue slices to investigate the distribution of drugs in specific organs or tissues.
Employ imaging techniques such as fluorescence imaging or mass spectrometry imaging to visualize and quantify drug distribution patterns within tissues.

Conduct hepatocyte and subcellular fraction incubations coupled with high-resolution mass spectrometry to identify metabolites.
Perform P450 inhibition/induction assays using hepatocytes/organoids and PCR arrays to uncover metabolism pathways and assess drug-drug interaction potentials.

Assess bile excretion mechanisms using in vitro cell models, such as hepatocyte cultures and membrane vesicle assays, to investigate the transporters involved in hepatic bile excretion.
Conduct ex vivo studies using liver tissue slices to evaluate bile excretion pathways and quantify biliary excretion rates.
Employ bile cannulation techniques in animal models to collect and analyze bile samples for the quantification of drug and metabolite concentrations.

Utilize transporter-overexpressing cell lines and membrane vesicle assays to reveal substrates, inhibitors, or inducers of hepatic and intestinal uptake/efflux proteins such as P-gp, BCRP, OATPs, and OCTs.

Evaluate the extent of drug binding to plasma proteins using in vitro assays and determine the unbound drug fraction available for distribution.
Investigate the influence of drug properties, such as lipophilicity or molecular weight, on plasma protein binding and subsequent distribution.

Our Technologies for Gastrointestinal and Hepatic Pharmacokinetic Studies

In Vivo Modeling

Rodents (rats, mice) for toxicokinetic, mass balance and drug-drug interaction tests.
Mini pigs for evaluating formulations and their effects on gastrointestinal physiology.
Isolated organ perfusion systems (liver, small intestine).
Larval zebrafish for high-throughput screening of metabolic stability.
Transgenic models (PXR, Mdr1a/1b KO) to study transporter effects.

Route of Administration

Intravitreal injection, oral, oropharynx, intranasal, inhalation, intratracheal, subcutaneous injection, intramuscular injection, intradermal injection, intravenous injection, intraperitoneal injection, continuous infusion, portal vein, duodenum.

Our Isotopic Labelling and Imaging Services

Isotopes: Including but not limited to ¹⁸F, ⁶⁸Ga, ⁸⁹Zr, ¹²⁴I, ⁶⁴Cu, ¹¹C, ¹³¹I, ¹²⁵I, ^99mTc, ⁸⁹Zr.
Positron Emission Tomography (PET): Employ PET imaging using radiolabeled tracers to visualize and quantify drug distribution in real-time.
Single-Photon Emission Computed Tomography (SPECT): Utilize SPECT imaging with gamma-emitting radiotracers to study drug distribution.
Magnetic Resonance Imaging (MRI): Utilize contrast agents, such as gadolinium-based agents, to visualize drug distribution in tissues with excellent anatomical detail.
Fluorescence Imaging: Employ fluorescent dyes or probes to visualize and quantify drug distribution in tissues.
Mass Spectrometry Imaging (MSI): Utilize MSI techniques to map the distribution of drugs and their metabolites in tissues based on their molecular masses.

At Ace Therapeutics, our dedicated team of experts provides thorough analysis, interpretation, and reporting of pharmacokinetic data, assisting in drug development programs for gastrointestinal and hepatic diseases. Whether you require absorption characterization, distribution mapping, metabolism assessment, transporter interaction studies, or toxicokinetic evaluations, our services provide valuable insights. Contact us today to discuss your specific pharmacokinetic research needs.

Our products and services are for research use only and can not be used for diagnostic or other purposes.